BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tancheva L, Petralia MC, Miteva S, Dragomanova S, Solak A, Kalfin R, Lazarova M, Yarkov D, Ciurleo R, Cavalli E, Bramanti A, Nicoletti F. Emerging Neurological and Psychobiological Aspects of COVID-19 Infection. Brain Sci 2020;10:E852. [PMID: 33198412 DOI: 10.3390/brainsci10110852] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Sodagar A, Javed R, Tahir H, Razak SIA, Shakir M, Naeem M, Yusof AHA, Sagadevan S, Hazafa A, Uddin J, Khan A, Al-harrasi A. Pathological Features and Neuroinflammatory Mechanisms of SARS-CoV-2 in the Brain and Potential Therapeutic Approaches. Biomolecules 2022;12:971. [DOI: 10.3390/biom12070971] [Reference Citation Analysis]
2 Wu Y, Rakotoarisoa M, Angelov B, Deng Y, Angelova A. Self-Assembled Nanoscale Materials for Neuronal Regeneration: A Focus on BDNF Protein and Nucleic Acid Biotherapeutic Delivery. Nanomaterials 2022;12:2267. [DOI: 10.3390/nano12132267] [Reference Citation Analysis]
3 El‐hayek E, Kahwagi G, Issy N, Tawil C, Younis N, Abou‐khalil R, Matar M, Hallit S. ‎Factors associated with coronavirus disease 2019 infection severity among a sample of Lebanese adults: Data from a cross‐sectional study. Health Science Reports 2022;5. [DOI: 10.1002/hsr2.654] [Reference Citation Analysis]
4 Morowitz JM, Pogson KB, Roque DA, Church FC. Role of SARS-CoV-2 in Modifying Neurodegenerative Processes in Parkinson’s Disease: A Narrative Review. Brain Sciences 2022;12:536. [DOI: 10.3390/brainsci12050536] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Rittmannsberger H, Barth M, Malik P, Malsiner-Walli G, Yazdi K. First-episode psychotic disorders in the wake of the COVID-19 pandemic: a descriptive review of casereports. Acta Neuropsychiatr 2022;:1-22. [PMID: 35357298 DOI: 10.1017/neu.2022.11] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Casoli T. SARS-CoV-2 Morbidity in the CNS and the Aged Brain Specific Vulnerability. Int J Mol Sci 2022;23:3782. [PMID: 35409141 DOI: 10.3390/ijms23073782] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Jennings G, Monaghan A, Xue F, Mockler D, Romero-Ortuño R. A Systematic Review of Persistent Symptoms and Residual Abnormal Functioning following Acute COVID-19: Ongoing Symptomatic Phase vs. Post-COVID-19 Syndrome. J Clin Med 2021;10:5913. [PMID: 34945213 DOI: 10.3390/jcm10245913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
8 Arjmand B, Roudsari PP, Alavi-Moghadam S, Rezaei-Tavirani M, Tayanloo-Beik A, Mehrdad N, Adibi H, Larijani B. Potential for Stem Cell-Based Therapy in the Road of Treatment for Neurological Disorders Secondary to COVID-19. Regen Eng Transl Med 2021;:1-15. [PMID: 34746370 DOI: 10.1007/s40883-021-00234-x] [Reference Citation Analysis]
9 Dragomanova S, Miteva S, Nicoletti F, Mangano K, Fagone P, Pricoco S, Staykov H, Tancheva L. Therapeutic Potential of Alpha-Lipoic Acid in Viral Infections, including COVID-19. Antioxidants (Basel) 2021;10:1294. [PMID: 34439542 DOI: 10.3390/antiox10081294] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
10 Jacobson KB, Rao M, Bonilla H, Subramanian A, Hack I, Madrigal M, Singh U, Jagannathan P, Grant P. Patients With Uncomplicated Coronavirus Disease 2019 (COVID-19) Have Long-Term Persistent Symptoms and Functional Impairment Similar to Patients with Severe COVID-19: A Cautionary Tale During a Global Pandemic. Clin Infect Dis 2021;73:e826-9. [PMID: 33624010 DOI: 10.1093/cid/ciab103] [Cited by in Crossref: 16] [Cited by in F6Publishing: 53] [Article Influence: 16.0] [Reference Citation Analysis]
11 Rittmannsberger H, Barth M, Malik P, Yazdi K. [Neuropsychiatric Aspects of COVID-19 - A Narrative Overview]. Fortschr Neurol Psychiatr 2021. [PMID: 34341978 DOI: 10.1055/a-1523-3850] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Chaudhuri KR, Rukavina K, McConvey V, Antonini A, Lorenzl S, Bhidayasiri R, Piemonte MEP, Lim SY, Richfield E, Walker R, Bouca-Machado R, Bajwah S, Gao W, Trivedi D, Miyasaki J. The impact of COVID-19 on palliative care for people with Parkinson's and response to future pandemics. Expert Rev Neurother 2021;21:615-23. [PMID: 33905283 DOI: 10.1080/14737175.2021.1923480] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
13 Ommati MM, Mobasheri A, Heidari R. Drug-induced organ injury in coronavirus disease 2019 pharmacotherapy: Mechanisms and challenges in differential diagnosis and potential protective strategies. J Biochem Mol Toxicol 2021;35:e22795. [PMID: 33973313 DOI: 10.1002/jbt.22795] [Reference Citation Analysis]
14 Dowd E, McKernan DP. Back to the future: lessons from past viral infections and the link with Parkinson's disease. Neuronal Signal 2021;5:NS20200051. [PMID: 33953960 DOI: 10.1042/NS20200051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Shahbazi M, Jafari M, Moulana Z, Sepidarkish M, Bagherzadeh M, Rezanejad M, Mirzakhani M, Javanian M, Bayani M, Sadeghi-Haddad-Zavareh M, Mehdinezhad H, Ghadimi R, Ghasemzadeh M, Shokuhi Rad A, Mohammadnia-Afrouzi M. Reduced frequency of T helper 17 and T helper 1 cells and their association with critical coronavirus disease 2019. APMIS 2021;129:271-9. [PMID: 33792109 DOI: 10.1111/apm.13129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kim HK, Cho YJ, Lee SY. Neurological Manifestations in Patients with COVID-19: Experiences from the Central Infectious Diseases Hospital in South Korea. J Clin Neurol 2021;17:435-42. [PMID: 34184452 DOI: 10.3988/jcn.2021.17.3.435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]